10x Genomics is trading at $57.39 (+10.30%) after Canaccord raised its price target to $60 from $50 and Piper Sandler lifted its target to $47 from $42.
- The move follows the August 6 earnings report, which showed $151 million in revenue and a narrower-than-expected loss.
- Early Atera demand was strong, and 2026 revenue guidance was raised to $610 million-$630 million.